1. Incidence of clinically diagnosed psoriatic arthritis in Sweden.
- Author
-
Exarchou S, Di Giuseppe D, Klingberg E, Sigurdardottir V, Wedrén S, Lindström U, Turesson C, Jacobsson LTH, Askling J, and Wallman JK
- Abstract
Objective: Prior incidence estimates of psoriatic arthritis (PsA) vary considerably. We aimed to assess the annual incidence of clinically diagnosed PsA among adults in Sweden 2014-2016, overall and stratified by age/sex/education/geography, and to investigate potential time-trends in incidence 2006-2018. Disease-modifying anti-rheumatic drug (DMARD) use during 2 years (y) from diagnosis was also examined., Methods: Patients (≥18y) with incident clinically diagnosed PsA in Sweden were identified from the National Patient Register (NPR) and/or the Swedish Rheumatology Quality register (SRQ). Population statistics, stratification parameters and DMARD information were retrieved from other nationwide registers. Incidence was estimated according to a base case (BC) definition (i.e., ≥1 main ICD-10 diagnosis of PsA [L40.5/M07.0-M07.3] from rheumatology/internal medicine in NPR, or a PsA diagnosis in SRQ during the relevant year, and no prior such diagnoses) and four different sensitivity analysis case definitions., Results: The mean annual incidence of clinically diagnosed PsA among adults in Sweden 2014-2016 was estimated at 21.77/100 000 person-years at risk (PY), according to the BC definition; 17.41/100 000 PY after accounting for diagnostic misclassification; and 15.78-28.83/100 000 PY across all sensitivity analyses. Incidence was slightly higher in females, lower in individuals with higher education (>12y) and peaked in the age-span 50-59y. No apparent increasing/decreasing time-trend was observed 2006-2018. Within 2y from diagnosis, 71.03% of patients had received DMARD-therapy (22.37% biologic/targeted synthetic DMARDs)., Conclusion: During 2014-2016, the annual incidence of clinically diagnosed PsA in the adult Swedish population was around 20/100 000 PY. Two years after diagnosis, almost 3/4 had received DMARD-therapy.
- Published
- 2024
- Full Text
- View/download PDF